Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Aims: This study examined the effects of pioglitazone on body weight and bone mineral density ( BMD ) prospectively in patients with impaired glucose tolerance as pioglitazone ( TZD ) increases body weight and body fat in diabetic patients and increases the risk of bone fractures. Methods: A total of 71 men and 163 women aged 49.3 (10.7) years [mean (s.d.)]; body mass index ( BMI ), 34.5 (5.9) kg/m 2 were recruited at five sites for measurements of body composition by dual energy X‐ray absorptiometry at baseline and at conversion to diabetes or study end, if they had not converted. Results: Mean follow‐up was 33.6 months in the pioglitazone group and 32.1 months in the placebo group. Body weight increased 4.63 ± 0.60 (m ± s.e.) kg in the pioglitazone group compared to 0.98 ± 0.62 kg in the PIO group (p < 0.0001). Body fat rose 4.89 ± 0.42 kg in the pioglitazone group compared to 1.41 ± 0.44 kg, (p < 0.0001) in placebo‐treated subjects. The increase in fat was greater in legs and trunk than in the arms. BMD was higher in all regions in men and significantly so in most. PIO decreased BMD significantly in the pelvis in men and women, decreased BMD in the thoracic spine and ribs of women and the lumbar spine and legs of men. Bone mineral content also decreased significantly in arms, legs, trunk and in the total body. Conclusions: Pioglitazone increased peripheral fat more than truncal fat and decreased BMD in several regions of the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 18×
“Men and women ≥18 years of age with IGT [2-h glucose of 140–199 mg/dl during a single oral glucose tolerance test (OGTT)] and body mass index (BMI) >25 kg/m2 were eligible if they had fasting plasma glucose (FPG) of 95–125 mg/dl and at least one of the following five additional risk factor for diabetes: (i) ≥1 compone…”
BackgroundInfluentialSelf-citationMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402 · cited 1×
“In contrast to the other TZDs, pioglitazone does not increase cardiovascular events [7,8], reduces coronary atheroma volume [9] and carotid intimal medial thickness [10–12], slows the loss of β-cell function [13] and improves insulin sensitivity [14].”
ResultSelf-citation
Cited by
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
“Bray GA [11] 2013 People with impaired glucose tolerance 53 Pioglitazone vs placebo 30–45 mg/d 33.”
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
Palavicini, J. P., Chavez-Velazquez, A., Fourcaudot, M., Tripathy, D., Pan, M., Norton, L., DeFronzo, R. A., & Shannon, C. E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.784391 · Cited by 36
Self-citationIpsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Metadata
- Authors
- Bray, G. A., Smith, S. R., Banerji, M. A., Tripathy, D., Clement, S. C., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R. E., Schwenke, D. C., Stentz, F. B., Reaven, P. D., & DeFronzo, R. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-05-07
- Volume
- 15
- Issue
- 10
- Pages
- 931-937
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2057254958
- Cited by
- 37
- References
- 16
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. https://app.cochat.ai/papers/10.1111/dom.12099
- The paper
- Bray, G. A., Smith, S. R., Banerji, M. A., Tripathy, D., Clement, S. C., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R. E., Schwenke, D. C., Stentz, F. B., Reaven, P. D., & DeFronzo, R. A. (2013). Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.